LianBio

OTC: LIANY · Healthcare · Biotechnology

PublicHQ Princeton, NJ · MercerCIK 0001831283Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 43

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, Piotroski F · ↓ listing tenure, market scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$110.3M

Employees

163

as of 2026-09-20

Market cap

$6.5M

as of 2026-09-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$110.3M-$110.3M2022

Operating income-$125.4M-$125.4M2022

Total assets$320.0M$320.0M2022

Liabilities$26.3M$26.3M2022

Equity$259.9M$259.9M2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is LianBio’s financial profile?

LianBio earned -$110.3M in FY2022 net income.

Peers · Healthcare

Lakewood-Amedex Biotherapeutics Inc. Common Stock——Qscreen Ai Inc.——Xcelerate Inc.——Revelation Biosciences, Inc.——KMA Holding, Inc.——Cann American Corp.——

Neighbors

Mercer →

Bristol-Myers Squibb Company$48.2B85A Clearway Energy, Inc.$1.4B54D Essential Properties Realty Trust, Inc.$561.2M71B Miami International Holdings, Inc. $1.4B43D UroGen Pharma Ltd.$109.8M55C Kardigan, Inc.$0——

Key facts

CEOAdam Leo Stone

SectorHealthcare

IndustryBiotechnology

HeadquartersPrinceton, NJ

ExchangeOTC: LIANY

Employees163

IPO date2021-11-01

Latest filings

8-K2024-02-13 8-K2023-12-26 8-K2023-12-20 8-K2023-12-19 8-K2023-12-06 8-K2023-12-01 8-K2023-11-13 10-Q2023-11-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.